ArticleJournal of thoracic disease2026
Can local consolidation therapy improve survival in EGFR-positive advanced non-small cell lung cancer after first-line TKI treatment?-a systematic review and meta-analysis.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Local consolidation therapy (LCT), which includes surgery or radiotherapy, has been shown to improve outcomes when combined with systemic therapy in advanced non-small cell lung cancer (NSCLC). However, as prior clinical studies often involved populations with heterogeneous driver oncogene status, it remains uncertain whether patients with epidermal growth factor receptor (EGFR)-mutant advanced NSCLC benefit from LCT following first-line tyrosine kinase inhibitor (TKI) treatment. We conducted a meta-analysis to evaluate the efficacy and safety of LCT in this specific population. Methods: We performed a systematic search of PubMed, Embase, and the Cochrane Library for studies involving patients with EGFR-mutant advanced (stage IV) NSCLC who received first-line TKI treatment. Key outcomes, including overall survival (OS), progression-free survival (PFS), and treatment-related adverse events (TRAEs), were compared between LCT plus TKI and TKI alone. Statistical analysis employed fixed- or random-effects models based on heterogeneity (I2). Results: Four clinical studies [three retrospective studies and one randomized controlled trial (RCT)] involving a total of 644 patients were included. Data on OS, PFS, and TRAEs were systematically extracted. Meta-analysis demonstrated that LCT was associated with significantly improved OS [hazard ratio (HR) =0.41, 95% confidence interval (CI): 0.35-0.48] and PFS (HR =0.30, 95% CI: 0.24-0.38) in EGFR-mutant advanced NSCLC patients following first-line TKI treatment. Furthermore, LCT did not significantly increase the risk of severe TRAEs [relative risk (RR) =0.91, 95% CI: 0.60-1.37] or Grade 1-2 TRAEs (RR =0.95, 95% CI: 0.83-1.10). Conclusions: For patients with EGFR-mutant advanced (stage IV) NSCLC receiving first-line TKI treatment, the addition of LCT can significantly improve both OS and PFS without increasing the incidence of TRAEs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.